<DOC>
	<DOCNO>NCT00250016</DOCNO>
	<brief_summary>The purpose study determine amount Aerosolized Liposomal-Nitro-20 ( S ) -Camptothecin ( L9NC ) patient blood tumor .</brief_summary>
	<brief_title>Pharmacology Study Aerosolized Liposomal 9-Nitro-20 ( S ) -Camptothecin ( L9NC )</brief_title>
	<detailed_description>Patients study ask allow researcher take piece normal endometrial tissue tumor tissue . No additional endometrial tissue take study surgically indicate resect patient tumor completely . Prior surgery , patient receive one dose L9NC outpatient clinic manner L9NC treatment receive . After tumor remove , tissue examine pathologist , take need diagnose residual disease . What need patient care use research . A piece tumor normal endometrial tissue surround tumor send Investigational Drug Program laboratory , locate Cancer Center , measure amount drug leave patient tumor . The patient tissue keep tissue collect patient , could take 10 year . The tissue use purpose . The sample label patient initial .</detailed_description>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Rubitecan</mesh_term>
	<criteria>Patients participate Phase II Study Aerosolized Liposomal 9Nitro20 ( S ) Camptothecin ( L9NC ) Patients Metastatic Recurrent Cancer Endometrium eligible . Not specify .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Endometrium</keyword>
	<keyword>Tissue</keyword>
	<keyword>L9NC</keyword>
</DOC>